Interventional technology firm Cook Medical has launched the Reform clinical trial, designed to evaluate its Formula balloon expandable stent for treating renal artery stenosis.
The trial will enroll up to 100 patients at up to 30 investigative sites throughout the U.S., according to the Bloomington, IN-based company. Initial results are expected to be available in the second quarter of 2010.
In other Cook news, the company has received U.S. Food and Drug Administration 510(k) clearance for its Celect vena cava filter. Celect is designed to prevent recurrent pulmonary embolism via placement in the vena cava, Cook said.
Related Reading
Cook debuts new AAA graft, November 14, 2007
Cook receives FDA nod for Zenith stent trial, September 24, 2007
Cook expands existing Cardica deal, September 20, 2007
Cook plans manufacturing expansion, September 18, 2007
Cook debuts SonoBiopsy catheter, August 6, 2007
Copyright © 2008 AuntMinnie.com
